June 20, 2018

Keytruda Conditionally Approved in US for Primary Mediastinal B-cell Lymphoma

News

The U.S. Food and Drug Administration has granted accelerated approval to Keytruda (pembrolizumab) for the treatment of relapsed or refractory primary mediastinal large B-cell lymphoma (PMBCL), making it the first anti-PD-1 therapy ... Read more

August 3, 2017

Kite Seeks EU Approval for CAR T-Cell Therapy in 3 Lymphoma Subtypes

News

Kite Pharma submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) requesting the approval of its CAR T-cell therapy, axicabtagene ciloleucel, as treatment for patients with certain ... Read more